Capricor’s Advisory Committee meeting with FDA to be held July 30, 2025

Capricor Therapeutics, which received early funding from CureDuchenne, announced regulatory updates for their Deramiocel program to treat Duchenne.  The FDA informed Capricor of its intent to hold an Advisory Committee meeting on July 30 of this year.   Capricor‘s manufacturing facility has completed inspection and the company is on track for a priority review with the PDUFA action date of August 31, 2025. 

Link to press release